<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104499">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01744054</url>
  </required_header>
  <id_info>
    <org_study_id>201209062</org_study_id>
    <nct_id>NCT01744054</nct_id>
  </id_info>
  <brief_title>Microsphere Localization Using Image Result for Positron Emission Tomography-Magnetic Resonance Imaging (PET/MRI) or Positron Emission Tomography-Computed Tomography (PET/CT) in Patients With Liver Disease</brief_title>
  <official_title>Pilot Study of Microsphere Localization Using PET/MRI or PET/CT in Patients With Liver Disease Following Radioembolization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The successful localization of the y90 microspheres by PET/MR and/or PET/CT scans would be a
      useful tool in individualizing patient care after the radioembolization procedure. The
      information from a PET/MR or PET/CT scan would allow for early evaluation of the technical
      success of the procedure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2012</start_date>
  <completion_date type="Anticipated">June 30, 2017</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate y90-PET/MRI and PET/CT for potential on reporting presence of extrahepatic deposition of microspheres</measure>
    <time_frame>1 day (one time event for patient)</time_frame>
    <description>A diagnostic radiologist and a nuclear medicine physician will evaluate the images and will determine any presence of extrahepatic deposition of microspheres.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate y90-PET/MRI and PET/CT for potential on reporting technical success of radioembolization</measure>
    <time_frame>1 day (one time event for patient)</time_frame>
    <description>A diagnostic radiologist and a nuclear medicine physician will evaluate the images and will determine whether technical success of the procedure can be determined. They will rate the images if they are 'adequate' to report on these two measures.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Liver Neoplasms</condition>
  <arm_group>
    <arm_group_label>PET/MR or PET/CT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients must have had radioembolization, within 72 hours of the PET/MR or PET/CT
Subjects will be asked to lie still within the scanner for up to 1.5 hours while images are acquired for the liver</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PET/MR</intervention_name>
    <arm_group_label>PET/MR or PET/CT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PET/CT</intervention_name>
    <arm_group_label>PET/MR or PET/CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant must successfully complete the MRI screening form if receiving an MRI

          -  Participant must be scheduled to undergo radioembolization for any indication

          -  Participant must be â‰¥ 18 years of age

          -  Participant must be able to understand and willing to sign an Institutional Review
             Board (IRB)-approved written informed consent document

        Exclusion Criteria:

          -  Participant must not have any contraindications to MRI scanning

          -  Patient must not be pregnant or breastfeeding

          -  If agreeing to MRI contrast, participant must not have renal insufficiency
             (glomerular filtration rate (GFR &lt; 30 mL/min/1.73 m2) measured within the past 60
             days

          -  If agreeing to MRI contrast, participant must not be on dialysis

          -  If agreeing to MRI contrast, participant must not have had a prior allergic reaction
             to gadolinium-based contrast agents

          -  PET/MRI or PET/CT is not able to be scheduled within 72 hours of radioembolization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Parag Parikh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Parag Parikh, M.D.</last_name>
    <phone>314-747-9614</phone>
    <email>parikh@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parag Parikh, M.D.</last_name>
      <phone>314-747-9614</phone>
      <email>parikh@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Kathryn Fowler, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard LaForest, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Garcia-Ramirez, M.S</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nael Saad, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Todd DeWees, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 3, 2017</lastchanged_date>
  <firstreceived_date>November 30, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
